ABC multidrug transporters: Structure, function and role in chemoresistance

Pharmacogenomics

Volumn 9, Issue 1, 2008, Pages 105-127

  Sharom, Frances J ^a  

^a UNIVERSITY OF GUELPH   (Canada)

Author keywords

ABC superfamily; ABCG2 (BCRP); ATP hydrolysis; Drug efflux; Drug therapy; MRP1 ABCC1; Multidrug resistance; P glycoproteinMDR1 ABCB1; Polymorphisms; Transport mechanism

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER C1; ANALGESIC AGENT; ANTHRACYCLINE DERIVATIVE; ANTIHISTAMINIC AGENT; BIRICODAR; BREAST CANCER RESISTANCE PROTEIN; CARDIAC GLYCOSIDE; CARRIER PROTEIN; CISPLATIN; DIGOXIN; DISULFIRAM; ELACRIDAR; FUMITREMORGIN C; GEFITINIB; GLYCOPROTEIN P; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; IMMUNOMODULATING AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PROTEINASE INHIBITOR; TACROLIMUS; TARIQUIDAR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VINCA ALKALOID; ZOSUQUIDAR; DRUG;

CANCER CHEMOTHERAPY; DRUG PROTEIN BINDING; DRUG TRANSPORT; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; INTRAHEPATIC CHOLESTASIS; LOW DRUG DOSE; PARKINSON DISEASE; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ANIMAL; CHEMISTRY; DRUG RESISTANCE; DRUG THERAPY; GENE; GENETIC POLYMORPHISM; GENETICS; METABOLISM; PHYSIOLOGY; PROTEIN BINDING;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE; DRUG THERAPY; GENES, MDR; HUMANS; MEMBRANE TRANSPORT PROTEINS; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, GENETIC; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 40949121607     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.1.105     Document Type: Review

References (187)

1. Dassa E, Bouige P: The ABC of ABCs: a phylogenetic and functional classification of ABC systems in living organisms. Res. Microbiol. 152, 211-229 (2001).
2. Dean M, Rzhetsky A, Allikmets R: The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 11, 1156-1166 (2001).
3. Sheps JA, Ralph S, Zhao Z, Baillie DL, Ling V: The ABC transporter gene family of Caenorhabditis elegans has implications for the evolutionary dynamics of multidrug resistance in eukaryotes. Genome Biol. 5, R15 (2004).
4. Borst P, Oude Elferink RP: Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 71, 537-592 (2002).
5. Schinkel AH, Jonker JW: Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev. 55, 3-29 (2003).
6. Gottesman MM, Ling V: The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett. 580, 998-1009 (2006).
7. Huang Y, Sadee W: Membrane transporters and channels in chemoresistaice and - sensitivity of tumor cells. Cancer Lett. 239, 168-182 (2006).
8. Litman T, Druley TE, Stein WD, Bates SE: From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell. Mol. Life Sci. 58, 931-959 (2001).
9. Özvegy C, Litman T, Szakács G et al.: Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem. Biophys Res. Commun. 285, 111-117 (2001).
10. Bosch I, Dunussi-Joannopoulos K, Wu RL, Furlong ST, Croop J: Phosphatidylcholine and phosphatidylethanolamine behave as substrates of the human MDR1 P-glycoprotein. Biochemistry 36, 5685-5694 (1997).
11. Romsicki Y, Sharom FJ: Phospholipid flippase activity of the reconstituted P-glycoprotein multidrug transporter. Biochemisay, 40, 6937-6947 (2001).
12. Eckford PD, Sharom FJ: The reconstituted P-glycoprotein multidrug transporter is a flippase for glucosylceramide and other simple glycosphingolipids. Biochem. J. 389, 517-526 (2005).
13. Ernest S, Bello-Reuss E: Secretion of platelet-activating factor is mediated by MDR1 P-glycoprotein in cultured human mesangial cells. J. Am. Soc. Nephrol. 10, 2306-2313 (1999).
14. Eckford PD, Sharom FJ: P-glycoprotein (ABCB1) interacts directly with lipid-based anti-cancer drugs and platelet-activating factors. Biochem. Cell Biol. 84, 1022-1033 (2006).
15. Bello-Reuss E, Ernest S, Holland OB, Hellmich MR: Role of multidrug resistance P-glycoprotein in the secretion of aldosterone by human adrenal NCI-H295 cells. Am. J. Physiol. Cell Physiol. 278, C1256-C1265 (2000).
16. Liu Y, Huang L, Hoffman T, Gosland M, Vore M: MDR1 substrates/modulators protect against β-estradiol-17β-D-glucuronide cholestasis in rat liver. Cancer Res. 56, 4992-4997 (1996).
17. Lam FC, Liu R, Lu P et al.: β-amyloid efflux mediated by p-glycoprotein. J. Neurochem. 76, 1121-1128 (2001).
18. Pawlik A, Baskiewicz-Masiuk M, Machalinski B, Safranow K, Gawronska-Szklarz B: Involvement of P-glycoprotein in the release of cytokines from peripheral blood mononuclear cells treated with methotrexate arid dexamethasone. J. Pharm. Pharmacol. 57, 1421-1425 (2005).
19. Ruetz S, Gros P: Phosphatidylcholine translocase: a physiological role for the mdr2 gene. Cell 77, 1071-1081 (1994).
20. Smith AJ, van Helvoort A, van Meer G et al.: MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J. Biol. Chem. 275, 23530-23539 (2000).
21. Bakos E, Homolya L: Portrait of multifaceted transporter, the multidrug resistance-associated protein 1 (MRP1/ABCC1). Pflugers Arch. Eur. J. Physiol. 453, 621-641 (2007).
22. Cole SP, Sparks KE, Fraser K et al.: Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 54, 5902-5910 (1994).
23. Ishikawa T, Tamura A, Saito H, Wakabayashi K, Nakagawa H: Pharmacogenomics of the human ABC transporter ABCG2: from functional evaluation to drug molecular design. Naturwissenschaften 92, 451-463 (2005).
24. Staud F, Pavek P: Breast cancer resistance protein (BCRP/ABCG2). Int. J. Biochem. Cell Biol. 37, 720-725 (2005).
25. Robert J, Jarry C: Multidrug resistance reversal agents. J Med. Chem. 46, 4805-4817 (2003).
26. Dayan G, Jault JM, Baubichon-Cortay H et al.: Binding of steroid modulators to recombinant cytosolic domain from mouse P-glycoprotein in close proximity to the ATP site. Biochemistry 36, 15208-15215 (1997).
27. Martin C, Berridge G, Mistry P, Higgins C, Charlton P, Callaghan R: The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br. J. Pharmacol. 128, 403-411 (1999).
28. Sauna ZE, Peng XH, Nandigama K. Tekle S, Ambudkar SV: The molecular basis of the action of disulfiram as a modulator of the multidrug resistance-linked ATP binding cassette transporters MDR1 (ABCB1) and MRP1 (ABCC1). Mol. Pharmacol. 65, 675-684 (2004).
29. Leslie EM, Deeley RG, Cole SPC: Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxical. Appl. Pharmacol. 204, 216-237 (2005).
30. Schinkel AH, Smit JJ, van Tellingen O et al.: Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77, 491-502 (1994).
31. Borst P, Schinkel AH: What have we learnt thus far from mice with disrupted P-glycoprotein genes? Eur. J. Cancer 32A. 985-990 (1996).
32. Wijnholds J, Scheffer GL, van der Valk M et al.: Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage. J. Exp. Med. 188, 797-808 (1998).
33. Zhou S, Morris JJ, Barnes YX, Lan L, Schuetz JD, Sorrentino BP: Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc. Natl Acad. Sci. USA 99, 12339-12344 (2002).
34. Doran A. Obach RS, Smith BJ et al.: The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab. Dispos. 33, 165-174 (2005).
35. Fromm MF: Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol. Sci. 25, 423-429 (2004).
36. van Tellingen O, Buckle T, Jonker JW, van der Valk MA, Begnen JH: P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo. Br. J. Cancer 89, 1776-1782 (2003).
37. Jonker JW, Merino G, Musters S et al.: The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat. Med. 11, 127-129 (2005).
38. van Herwaarden AE, Wagenaar E, Merino G et al.: Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B-2) into milk. Mol. Cell. Biol. 27, 1247-1253 (2007).
39. Jonker JW, Buitelaar M, Wagenaar E et al.: The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc. Natl Acad. Sci. USA 99, 15649-15654 (2002).
40. Krishnamurthy P, Ross DD, Nakanishi T et al.: The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J. Biol. Chem. 279, 24218-24225 (2004).
41. Frelet A, Klein M: Insight in eukaryotic ABC transporter function by mutation analysis. FEBS Lett. 580, 1064-1084 (2006).
42. Locher KP, Lee AT, Rees DC: The E. coli BtuCD structure: a framework for ABC transporter architecture and mechanism. Science 296, 1091-1098 (2002).
43. Hopfner KP, Karcher A, Shin DS et al.: Structural biology of Rad50 ATPase: ATP-driven conformational control in DNA double-strand break repair and the ABC-ATPase superfamily. Cell 101, 789-800 (2000).
44. Smith PC, Karpowich N, Millen L et al. ATP binding to the motor domain from an ABC transporter drives formation of a nucleotide sandwich dimer. Mol. Cell 10, 139-149 (2002).
45. Hanekop N, Zaitseva J, Jenewein S, Holland IB, Schmitt L: Molecular insights into the mechanism of ATP-hydrolysis by the NBD of the ABC-transporter HlyB. FEBS Lett. 580, 1036-1041 (2006).
46. Liu R. Sharom FJ: Fluorescence studies on the nucleotide binding domains of the P-glycoprotein multidrug transporter. Biochemistry 36, 2836-2843 (1997).
47. Lerner-Marmarosh N. Omi K, Urbatsch IL, Gros P, Benior AE: Large scale purification of detergent-soluble P-glycoprotein from Pichia pastoris cells and characterization of nucleotide binding properties of wild-type, Walker A, and Walker B mutant proteins. J. Biol. Chem. 274, 34711-34718 (1999).
48. Sharom FJ, Yu X, Chu JWK, Doige CA: Characterization of the ATPase activity of P-glycoprotein from multidrug-resistant Chinese hamster ovary cells. Biochem. J. 308, 381-390 (1995).
49. Urbatsch IL, al-Shawi MK, Senior AE: Characterization of the ATPase activity of purified Chinese hamster P-glycoprotein. Biochemistry 33, 7069-7076 (1994).
50. Mao QC, Leslie EM, Deeley RG, Cole SPC: ATPase activity of purified and reconstituted multidrug resistance protein MRP1 from drug-selected H69AR cells. Biochim. Biopbys. Acta 1461, 69-82 (1999).
51. Doige CA, Yu X, Sharom FJ: ATPase activity of partially purified P-glycoprotein from multidrug-resistant Chinese hamster ovary cells. Biochim. Biophys. Acta 1109, 149-160 (1992).
52. Garrigos M, Mir LM. Orlowski S: Competitive and non-competitive inhibition of the multidrug-resistance-associated P-glycoprotein ATPase-further experimental evidence for a multisite model. Eur. J. Biochem. 244, 664-673 (1997).
53. Litman T, Zeuthen T, Skovsgaard T, Stein WD: Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochim. Biophys. Acta 1361, 169-176 (1997).
54. Doige CA, Yu X, Sharom FJ: The effects of lipids and detergents on ATPase-active P-glycoprotein. Biochim. Biophys. Acta 1146, 65-72 (1993).
55. Urbatsch IL, Senior AE: Effects of lipids on ATPase activity of purified Chinese hamster P-glycoprotein Arch. Biochem. Biophys. 316, 135-140 (1995).
56. Litman T, Zeuthen T, Skovsgaard T, Stein WD: Structure-activity relationships of P-glycoprotein interacting drugs: kinetic characterization of their effects on ATPase activity. Biochim. Biophys. Acta 1361, 159-168 (1997).
57. Omote H, al-Shawi MK: Interaction of transported drugs with the lipid bilayer and P-glycoprotein through a solvation exchange mechanism. Biophys. J. 90, 4046-4059 (2006).
58. Senior AE, al-Shawi MK, Urbatsch IL: The catalytic cycle of P-glycoprotein. FEBS Lett. 377, 285-289 (1995).
59. Gao M, Cui HR, Loe DW et al.: Comparison of the functional characteristics of the nucleotide binding domains of multidrug resistance protein 1. J. Biol. Chem. 275, 13098-13108 (2000).
60. Qu Q, Russell PL, Sharom FJ: Stoichiometry and affinity of nucleotide binding to P-glycoprotein during the catalytic cycle. Biochemistry 42, 1170-1177 (2003).
61. Delannoy S, Urbatsch IL, Tombline G, Senior AE, Vogel PD: Nucleotide binding to the multidrug resistance P-glycoprotein as studied by ESR spectroscopy. Biochemistry 44, 14010-14019 (2005).
62. Bakos E, Evers R, Szakács G et al.: Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain. J. Biol. Chem. 273, 32167-32175 (1998).
63. Westlake CJ. Cole SPC, Deeley RG: Role of the NH2-terminal membrane spanning domain of multidrug resistance protein 1/ABCC1 in protein processing and trafficking. Mol. Biol. Cell 16, 2483-2492 (2005).
64. Yang YY, Liu Y, Dong ZZ et al.: Regulation of function by dimerization through the amino-terminal membrane-spanning domain of human ABCC1/MRP1. J. Biol. Chem. 282, 8821-8830 (2007).
65. Rosenberg MF, Callaghan R, Modok S, Higgins CF, Ford RC: Three-dimensional structure of P-glycoprotein - the transmembrane regions adopt an asymmetric configuration in the nucleotide-bound state. J Biol. Chem. 280, 2857-286?(2005).
66. Qu Q, Sharom FJ: FRET analysis indicates that the two ATPase active sites of the P-glycoprotein multidrug transporter are closely associated. Biochemistry 40, 1413-1422 (2001).
67. Urbatsch IL, Gimi K, Wilke-Mounts S et al.: Cysteines 431 and 1074 are responsible for inhibitory disulfide cross-linking between the two nucleotide-binding sites in human P-glycoprotein. J. Biol. Chem. 276, 26980-26987 (2001).
68. Loo TW, Bartlett MC, Clarke DM: The 'LSGGQ' motif in each nucleotide-binding domain of human P-glycoprotein is adjacent to the opposing Walker A sequence. J. Biol. Chem. 277, 41303-41306 (2002).
69. Rosenberg MF, Mao QC, Holzenburg A, Ford RC, Deeley RG, Cole SPC: The structure of the multidrug resistance protein 1 (MRP1/ABCC1) - crystallization and single-particle analysis. J. Biol. Chem. 276, 16076-16082 (2001).
70. McDevitt CA, Collins RF, Conway M et al.: Purification and 3D structural analysis of oligomeric human multidrug transporter ABCG2. Structure 14, 1623-1632 (2006).
71. Loo TW, Clarke DM: Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J. Membr. Biol. 206, 173-185 (2005).
72. Shapiro AB, Ling V: Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur. J. Biochem. 250, 130-137 (1997).
73. Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R: Communication between multiple drug binding sites on P-glycoprotein. Mol. Pharmacol. 58, 624-632 (2000).
74. Loo TW, Bartlett MC, Clarke DM: Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein. J. Biol. Chem. 278, 39706-39710 (2003).
75. Lugo MR, Sharom FJ: Interaction of LDS-751 and rhodamine 123 with P-glycoprotein: evidence for simultaneous binding of both drugs. Biochemistry 44, 14020-14029 (2005).
76. Loo TW, Clarke DM: Do drug substrates enter the common drug-binding pocket of P-glycoprotein through 'gates'? Biochem. Biophys. Res. Commun. 329, 419-422 (2005).
77. Loo TW, Bartlett MC, Clarke DM: Substrate-induced conformational, changes in the transmembrane segments of human P-glycoprotein - direct evidence for the substrate-induced fit mechanism for drug binding. J. Biol. Chem. 278, 13603-13606 (2003).
78. Schumacher MA, Miller MC, Brennan RG: Structural mechanism of the simultaneous binding of two drugs to a multidrug-binding protein. EMBO J. 23, 2923-2930 (2004).
79. Loo TW, Bartlett MC, Clarke DM: The drug-binding pocket of the human multidrug resistance P-glycoprotein is accessible to the aqueous medium. Biochemistry 43, 12081-12089 (2004).
80. Lugo MR, Sharom FJ: Interaction of LDS-751 with P-glycoprotein and mapping of the location of the R drug binding site. Biochemistry 44, 643-655 (2005).
81. Sharom FJ, Liu R, Qu Q, Romsicki Y: Exploring the structure and function of the P-glycoprotein multidrug transporter using fluorescence spectroscopic tools. Seminars Cell Dev. Biol. 12, 257-266 (2001).
82. Seelig A: A general pattern for substrate recognition by P-glycoprotein. Eur. J. Biochem. 251, 252-261 (1998).
83. Cianchetta G, Singleton RW, Zhang M et al.: A pharmacophore hypothesis for P-glyroprotein substrate recognition using GRIND-based 3D-QSAR. J. Med. Chem. 48, 2927-2935 (2005).
84. Pajeva IK, Wiese M: Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: Explanation of structural variety (hypothesis). J. Med. Chem. 45, 5671-5686 (2002).
85. Pawagi AB, Wang J, Silverman M, Reithmeier RA, Deber CM: Transmembrane aromatic amino acid distribution in P-glycoprotein. A functional role in broad substrate specificity. J. Mol. Biol. 235, 554-564 (1994).
86. Liu R, Siemiarczuk A, Sharom FJ: Intrinsic fluorescence of the P-glycoprotein multidrug transporter: sensitivity of tryptophan residues to binding of drugs and nucleotides. Biochemistry 39, 14927-14938 (2000).
87. Clark, Kerr ID, Callaghan R: Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter. Br. J. Pharmacol. 149, 506-515 (2006).
88. Deeley RG, Cole SPC: Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). FEBS Lett. 580, 1103-1111 (2006).
89. Campbell JD, Koike K, Moreau C, Sansom MSP, Deeley RG, Cole SPC: Molecular modeling correctly predicts the functional importance of Phe594 in transmembrane Helix 11 of the multidrug resistance protein, MRP1 (ABCC1). J. Biol. Chem. 279, 463-468 (2004).
90. Pinkett HW, Lee AT, Lum P, Locher KP, Rees DC: An inward-facing conformation of a putative metal-chelate-type ABC transporter. Science 315, 373-377 (2007).
91. Hollenstein K, Frei DC, Locher KP: Structure of an ABC transporter in complex with its binding protein. Nature 446, 213-216 (2007).
92. Dawson RJ, Locher KP: Structure of a bacterial multidrug ABC transporter. Nature 443, 180-185 (2006).
93. Locher KP, Berths E: ABC transporter architecture and mechanism: implications from the crystal structures of BtuCD and BtuF. FEBS Lett. 564, 264-268 (2004).
94. Reyes CL, Ward A, Yu J, Chang G: The structures of MsbA: Insight into ABC transporter-mediated multidrug efflux. FEBS Lett. 580, 1042-1048 (2006).
95. Chang G, Roth CB, Reyes CL, Pornillos O, Chen YJ, Chen AP: Structure of MsbA from E. coli: A homolog of the multidrug resistance ATP binding cassette (ABC) transporters (Retraction of vol 293, pg 1793, 2001). Science 314, 1875 (2006).
96. Seigneuret M, Garnier-Suillerot A: A structural model for the open conformation of the mdr1 P-glycoprotein based on the MsbA crystal structure. J. Biol. Chem. 278, 30115-30124 (2003).
97. Stenham DR, Campbell JD, Sansom MS, Higgins CF, Kerr ID, Linton KJ: An atomic detail model for the human ATP binding cassette transporter P-glycoprotein derived from disulfide cross-linking and homology modeling. FASEB J. 17, 2287-2289 (2003).
98. Callaghan R, Ford RC, Kerr ID: The translocation mechanism of P-glycoprotein. FEBS Lett. 580, 1056-1063 (2006).
99. Hrycyna CA, Ramachandra M, Germann UA, Cheng PW, Pastan I, Gottesman MM: Both ATP sites of human P-glycoprotein are essential but not symmetric. Biochemistry 38, 13887-13899 (1999).
100. Tombline G, Bartholomew LA, Urbatsch IL, Senior AE: Combined mutation of catalytic glutamate residues in the two nucleotide binding domains of P-glycoprotein generates a conformation that binds ATP and ADP tightly. J. Biol. Chem. 279, 31212-31220 (2004).
101. Janas E, Hofacker M, Chen M, Gompf S, Van der Does C, Tampé R: The ATP hydrolysis cycle of the nucleotide-binding domain of the mitochondrial ATP-binding cassette transporter Mdl1p. J. Biol. Chem. 278, 26862-26869 (2003).
102. Ambudkar SV, Kim IW, Sauna ZE: The power of the pump: mechanisms of action of P-glycoprotein (ABCB1). Eur. J. Pharm. Sci. 27, 392-400 (2006).
103. Liu R, Sharom FJ: Site-directed fluorescence labeling of P-glycoprotein on cysteine residues in the nucleotide binding domains. Biochemistry 35, 11865-11873 (1996).
104. Higgins CF, Linton KJ: The ATP switch model for ABC transporters. Nature Struct. Biol. 11, 918-926 (2004).
105. Higgins CF, Gottesman MM: Is the multidrug transporter a flippase? Trends Biochem. Sci. 17, 18-21 (1992).
106. Gatlik-Landwojtowicz E, Aanismaa P, Seelig A: Quantification and characterization of P-glycoprotein-substrate interactions. Biochemistry 45, 3020-3032 (2006).
107. Romsicki Y, Sharom FJ: The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter. Biochemistry 38, 6887-6896 (1999).
108. Lu P, Liu R, Sharom FJ: Drug transport by reconstituted P-glycoprotein in proteoliposomes. Effect of substrates and modulators, and dependence on bilayer phase state. Eur. J. Biochem. 268, 1687-1697 (2001).
109. Eytan GD, Regev R, Oren G, Assaraf YG: The role of passive transbilayer drug movement in multidrug resistance and its modulation. J. Biol. Chem. 271, 12897-12902 (1996).
110. Sharom FJ, Lugo MR, Eckford PD: New insights into the drug binding, transport and lipid flippase activities of the P-glycoprotein multidrug transporter. J. Bioenerg. Biomembr. 37, 481-487 (2005).
111. Polgar O, Bates SE: ABC transporters in the balance: is there a role in multidrug resistance? Biochem. Soc. Trans. 33, 241-245 (2005).
112. Steinbach D, Legrand O: ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra? Leukemia 21, 1172-1176 (2007).
113. Diestra JE, Scheffer GL, Català I et al.: Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J. Pathol. 198, 213-219 (2002).
114. Robey RW, Polgar O, Deeken J, To KW, Bates SE: ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev. 26, 39-57 (2007).
115. Hipfner DR, Deeley RG, Cole SPC: Structural mechanistic and clinical aspects of MRP1. Biochim. Biophys. Acta 1461, 359-376 (1999).
116. Boumendjel A, Baubichon-Cortay H, Trompier D, Perrotton T, Di Pietro A: Anticancer multidrug resistance mediated by MRP1: Recent advances in the discovery of reversal agents. Med. Res. Rev. 25, 453-472 (2005).
117. Sugimoto Y, Tsukahara S, Ishikawa E, Mitsuhashi J: Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics. Jap. J. Cancer Res. 96, 457-465 (2005).
118. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM: Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5, 219-234 (2006).
119. Minderman H, O'Loughlin KL, Pendyala L, Baer MR: VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin. Cancer Res. 10, 1826-1834 (2004).
120. Hermann DM, Bassetti CL. Implications of ATP-binding cassette transporters for brain pharmacotherapies. Trends Pharmacol. Sci. 28, 128-134 (2007).
121. Loescher W, Potschka H: Drug resistance in brain diseases and the role of drug efflux transporters. Nat. Rev. Neurosci. 6, 591-602 (2005).
122. Schinkel AH: P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv. Drug Deliv. Rev. 36, 179-194 (1999).
123. Breedveld P, Pluim D, Cipriani G et al.: The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevecc®): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res. 65, 2577-2582 (2005).
124. Wijnholds J, De Lange ECM, Scheffer GL et al.: Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J. Clin. Invest. 105, 279-285 (2000).
125. Breedveld P, Beijnen JH, Schellens JHM: Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol. Sci. 27, 17-24 (2006).
126. Choudhuri S, Klaassen CD: Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 ( MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int. J. Toxicol. 25, 231-259 (2006).
127. Kioka N, Tsubota J, Kakehi Y et al.: P-glycoprotein gene (MDR1) cDNA from human adrenal: normal P-glycoprotein carries Gly185 with an altered pattern of multidrug resistance. Biochem. Biophys. Res. Commun. 162, 224-231 (1989).
128. Chen G, Duran GE, Steger KA et al.: Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins. J. Biol. Chem. 272, 5974-5982 (1997).
129. Leschziner GD, Andrew T, Pirmohamed M, Johnson MR: ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J. 7, 154-179 (2007).
130. Marzolini C, Paus E, Buclin T, Kim RB: Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Clin. Pharmacol. Ther. 75, 13-33 (2004).
131. Allabi AC, Horsmans Y, Issaoui B, Gala JL: Single nucleotide polymorphisms of ABCB1 (MDR1) gene and distinct haplotype profile in a West Black African population. Eur. J. Clin. Pharmacol. 61, 97-102 (2005).
132. Kimchi-Sarfaty C, Marple AH, Shinar S et al.. Ethnicity-relaxed polymorphisms ana haplotypes in the human ABCB1 gene. Pharmacogenomics 8, 29-39 (2007).
133. Schwab M, Eichelbaum M, Fromm MF: Genetic polymorphisms of the human MDR1 drug transporter. Annu. Rev. Pharmacol. Toxicol. 43, 285-307 (2003).
134. Leschziner G, Zabaneh D, Pirmohamed M et al.: Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance. Pharmacogenet. Genomics 16, 439-450 (2006).
135. Kim RB, Leake BF, Choo EF et al.: Identification of functionally variant MDR1 alleles among European Americans and African-Americans. Clin. Pharmacol. Ther. 70, 189-199 (2001).
136. Kimchi-Sarfaty C, Oh JM, Kim IW et al.: A 'silent' polymorphism in the MDR1 gene changes substrate specificity. Science 315, 525-528 (2007).
137. Kimchi-Sarfaty C, Gribar JJ, Gottesman MM: Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol. Pharmacol. 62, 1-6 (2002).
138. Morita N, Yasumori T, Nakayama K: Human MDR1 polymorophism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem. Pharmacol. 65, 1843-1852 (2003).
139. Sakurai A, Onishi Y, Hirano H et al.: Quantitative structure-activity relationship analysis and molecular dynamics simulation to functionally validate nonsynonymous polymorphisms of human ABC transporter ABCB1 (P-glycoprotein/MDR1). Biochemistry 46, 7678-7693 (2007).
140. Woodahl EL, Yang ZP, Bui T, Shen DD, Ho RJY: MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. AIDS 19, 1617-1625 (2005).
141. Hoffmeyer S, Burk O, Von Richter O et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA 97, 3473-3478 (2000).
142. Fellay J, Marzolini C, Meaden ER et al.: Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359, 30-36 (2002).
143. Brumme ZL, Dong WW, Chan KJ et al.: Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response. AIDS 17, 201-208 (2003).
144. Saitoh A, Singh KK, Powell CA et al.: An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS 19, 371-380 (2005).
145. Siddiqui A, Kerb R, Weale ME et al.: Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N. Engl. J. Med. 348, 1442-1448 (2003).
146. Sills GJ, Mohanraj R, Butler E et al.: Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia 46, 643-647 (2005).
147. Tan NCK, Heron SE, Scheffer IE et al.: Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology 63, 1090-1092 (2004).
148. Basic S, Hajnsek S, Poljakovic Z, Basic M: Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia 47, 449 (2006).
149. Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ: Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Am. J. Cardiol. 93, 1046-1050 (2004).
150. Bercovich D, Friedlander Y, Korem S et al.: The association of common SNPs and haplotypes in the CETP and MDR1 genes with lipids response to fluvastatin in familial hypercholesterolemia. Atherosclerosis 185, 97-107 (2006).
151. Thompson JF, Man M, Johnson KJ et al.: An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J. 5, 352-358 (2005).
152. -/- mice results in colitis that progresses to dysplasia. Am. J. Pathol. 166, 1793-1806 (2005).
153. Brant SR, Panhuysen CIM, Nicolae D et al.: MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am. J. Hum. Genet. 73, 1282-1292 (2003).
154. Schwab M, Schaeffeler E, Marx C et al.: Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 124, 26-33 (2003).
155. Potocnik U, Ferkolj I, Glavac D, Dean M: Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn disease and ulcerative colitis. Genes Immun. 5, 530-539 (2004).
156. Osswald E, Johne A, Laschinski G et al.: Association of MDR1 genotypes with susceptibility to colorectal cancer in older non-smokers. Eur. J. Clin. Pharmacol. 63, 9-16 (2007).
157. Kurzawski M, Drozdzik M, Suchy J et al.: Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients. Eur. J. Clin. Pharmacol. 61, 389-394 (2005).
158. Potocnik U, Glavac MR, Golouh R, Glavac D: The role of P-glycoprotein (MDR1) polymorphisms and mutations in colorectal cancer. Pflugers Arch. 442, R182-R183 (2001).
159. Siegsmund M, Brinkmann U, Schäffeler E et al.: Association of the P-glycoprotein transporter MDR1 C3435T polymorphism with the susceptibility to renal epithelial tumors. J Am. Soc. Nephrol. 13, 1847-1854 (2002).
160. Uhr M, Ebinger M, Rosenhagen MC, Grauer MT: The anti-Parkinson drug budipine is exported actively out of the brain by P-glycoprotein in mice. Neurosci. Lett. 383, 73-76 (2005).
161. Leschziner GD, Andrew T, Leach JP et al.: Common ABCB1 polymorphisms are not associated with multidrug resistance in epilepsy using a gene-wide tagging approach. Pharmacogenet. Genomics 17, 217-220 (2007).
162. Shahwan A, Murphy K, Doherty C et al.: The controversial association of ABCB1 polymorphisms in refractory epilepsy: an analysis of multiple SNPs in an Irish population. Epilepsy Res. 73, 192-198 (2007).
163. Conseil G, Deeley RG, Cole SP: Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters. Pharmacogenet. Genomics 15, 523-533 (2005).
164. Wang Z, Wang B, Tang K, Lee EJ, Chong SS, Lee CG: A functional polymorphism within the MRP1 gene locus identified through its genomic signature of positive selection. Hum. Mol. Genet. 14, 2075-2087 (2005).
165. Oselin K, Mrozikiewicz PM, Gaikovitch E, Pähkla R, Roots I: Frequency of MRP1 genetic polymorphisms and their functional significance in Caucasians: detection of a novel mutation G816A in the human MRP1 gene. Eur. J. Clin. Pharmacol. 59, 347-350 (2003).
166. Letourneau IJ, Deeley RG, Cole SP: Functional characterization of non-synonymous single nucleotide polymorphisms in the gene encoding human multidrug resistance protein 1 (MRP1/ABCC1). Pharmacogenet. Genomics 15, 647-657 (2005).
167. Conrad S, Kauffmann HM, Ito K et al.: A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. Pharmacogenetics 12, 321-330 (2002).
168. Leslie EM, Létourneau IJ, Deeley RG, Cole SPC: Functional and structural consequences of cysteine substitutions in the NH2 proximal region of the human multidrug resistance protein 1 (MRP1/ABCC1). Biochemistry 42, 5214-5224 (2003).
169. Zamboni WC, Bowman LC, Tan M et al.: Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. Cancer Chemother. Pharmacol. 43, 454-460 (1999).
170. Tamura A, Watanabe M, Saito H et al.: Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: Identification of alleles that are defective in porphyrin transport. Mol. Pharmacol. 70, 287-296 (2006).
171. Kondo C, Suzuki H, Itoda M et al.: Functional analysis of SNPs variants of BCRP/ABCG2. Pharm. Res. 21, 1895-1903 (2004).
172. Morisaki K, Robey R. Oezvegy-Laczka C et al.: Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother. Pbarmacol. 56; 161-172 (2005).
173. Mizuarai S, Aozasa N, Kotani H: Single nucleotide polymorphisms resuit in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int. J. Cancer 109, 238-246 (2004).
174. Tamura A, Wakabayashi K, Onishi Y et al.: Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2. Cancer Sci. 98, 231-239 (2007).
175. Cervenak J, Andrikovics H, Oezvegy-Laczka C et al.: The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicology. Cancer Lett. 234, 62-72 (2006).
176. Kobayashi D, Ieiri I, Hirota T et al.: Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab. Dispos. 33, 94-101 (2005).
177. de Jong FA, Marsh S, Mathijssen RH et al.: ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin. Cancer Res. 10, 5889-5894 (2004).
178. Sparreboom A, Loos WJ, Burger H et al.: Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer Biol. Ther. 4, 650-658 (2005).
179. Sparreboom A, Gelderblom H, Marsh S et al.: Diflomotecan pharmacokinetics in celation to ABCG2 421C>A genotype. Clin. Pharmacol. Ther. 76, 38-44 (2004).
180. Zamboni WC, Ramanathan RK, McLeod HL et al.: Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes. Invest. New Drugs 24, 393-401 (2006).
181. Li J, Cusatis G, Brahmer J et al.: Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther. 6, 432-438 (2007).
182. Korenaga Y, Naito K, Okayama N et al.: Association of the BCRPC421A polymorphism with nonpapillary renal cell carcinoma. Int. J. Cancer 117, 431-434 (2005).
183. Honjo Y, Hrycyna CA, Yan QW et al.: Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ ABCP-overexpressing cells. Cancer Res. 61, 6635-6639 (2001).
184. Mitomo H, Kato R, Ito A et al.: A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport. Biochem. J. 373, 767-774 (2003).
185. Zhang JT, Ling V: Study of membrane orientation and glycosylated extracellular loops of mouse P-glycoprotein by in vitro translation. J. Biol. Chem. 266, 18224-18232 (1991).
186. Hipfner DR, Almquist KC, Leslie EM et al.: Membrane topology of the multidrug resistance protein (MRP). A study of glycosylation-site mutants reveals an extracytosolic NH2 terminus. J. Biol. Chem. 272, 23623-23630 (1997).
187. Diop NK, Hrycyna CA: N-linked glycosylation of the human ABC transporter ABCG2 on asparagine 596 is not essential for expression, transport activity, or trafficking to the plasma membrane. Biochemistry 44, 5420-5429 (2005).